Claims

1. Use of N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy) benzylamine (idalopirdine) and donepezil in the manufacture of a medicament for combination therapy of Parkinson's disease, wherein the treatment of Parkinson's disease consist in reducing falls in a patient with Parkinson's disease.

2. Use of a composition comprising N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy) benzylamine (idalopirdine) and donepezil in the manufacture of a medicament for treatment of Parkinson's disease, wherein the treatment of Parkinson's disease consist in reducing falls in a patient with Parkinson's disease.

3. The use according to claims 1 or 2, wherein, the dose of donepezil is from 1 to 30 mg, or from 5 to 23 mg.

4. The use according to any of claims 1 to 3, wherein the daily dose of idalopirdine is from 10 mg to 100 mg, or from 30 mg to 60 mg.